INTRODUCTION {#s1}
============

Warburg Micro syndrome (WARBM; MIM614225) and Martsolf syndrome (MS; MIM212720) represent the severe and mild forms, respectively, of a clinical syndrome characterized by the association of congenital cataracts, microcephaly, intellecutual disability, and hypogonadism ([@MCS005033XUC1]; [@MCS005033XUC3]). Compared to the WARBM phenotype, individuals with MS lack optic atrophy; have less severe functional visual impairment; do not have polymicrogyria or corpus callosal defects on brain imaging; have milder intellectual disability; and have muscular spasticity restricted to their lower limbs. Four genes (*RAB3GAP1, RAB3GAP2, RAB18*, and *TBC1D20*) are associated with WARBM/MS. Pathogenic variants in these genes result in dysfunctions of a RAB18, a GTPase, either directly (*RAB18*) or indirectly (*RAB3GAP1*, *RAB3GAP2*, *TBC1D20*) ([@MCS005033XUC12]; [@MCS005033XUC11]) and in RAB18 dysregulation and are thus believed to contribute to the disease pathology in both WARBM and MS via disruptions of these biologic pathways.

Although hypogonadism is a key feature in the WARBM/MS spectrum, most reproductive phenotypes in individuals with WARBM/MS ([@MCS005033XUC20]; [@MCS005033XUC14]; [@MCS005033XUC13]; [@MCS005033XUC1]; [@MCS005033XUC12]; [@MCS005033XUC8]; [@MCS005033XUC11]) have only been ascertained prepubertally (i.e., in infancy or prepuberty) and longitudinal studies regarding pubertal transition in these patients are also lacking. In addition, there is contradictory information regarding the nature of the hypogonadism (i.e., primary vs. secondary) in the handful of clinical reports involving adolescent/adult patients. In the initial report, two adult males had hypergonadotropism but with normal serum testosterone levels, suggestive of a compensated state of primary hypogonadism (i.e., a gonadal defect) ([@MCS005033XUC17]). In contrast, a 17-yr-old prepubertal female with MS and primary amenorrhea was subsequently reported who had hypogonadotropic hypogonadism ([@MCS005033XUC14]), suggesting secondary hypogonadism (i.e., a defect in hypothalamus and/or anterior pituitary). Unfortunately, genetic studies were not included in these prior reports. Herein, we describe a genotype-guided study that identified novel pathogenic variants in *RAB3GAP2* in an adult patient fulfilling clinical criteria for MS with complete absence of puberty and hypogonadotropic hypogonadism (suggesting underlying hypothalamic and/or pituitary defect) associated with *RAB3GAP2*-related MS.

RESULTS {#s2}
=======

Clinical Presentation and Family History {#s2a}
----------------------------------------

A female proband, born to nonconsanguineous parents, presented at 2 wk of age with bilateral cataracts and underwent lensectomies and subsequent strabismus repair. In late infancy, she was also noted to have hearing difficulties. Initially, the proband attended a school for visually impaired and, upon recognition of moderate learning difficulties, was transferred to a school for special education needs. Although she showed steady linear growth, she remained shorter than her peers throughout childhood. Other developmental milestones were also significantly delayed (walking at 2½ yr of age, speech initiation at 3 yr of age). Auditory testing showed low tone hearing loss (1000--6000 Hz---audible at threshold 20--30 dB, but reduced hearing at 250 and 500 Hz---audible at threshold 50--60 dB). At 17 yr of age, she presented to her endocrinologist with absent thelarche and menarche. She reported a normal sense of smell, and her physical examination revealed bilateral clinodactyly (radial, F5) and bilateral cutaneous syndactyly (partial fusion, T2--3). She had Tanner II axillary hair and Tanner IV pubic hair. Biochemical evaluation confirmed hypogonadotropic hypogonadism (LH: 0.2 IU/L; FSH: 0.8 IU/L; estradiol \[E~2~\]: 49 pmol/L \[reference range: 55--1284 pmol/L\]) with otherwise normal baseline anterior pituitary functions (prolactin, thyroid function tests, cortisol, and IGF-1). A cranial MRI showed a normal pituitary and intact olfactory structures. No polymicrogyria was noted and her corpus callosum was normal. Pelvic ultrasound showed a \<1-cm, rudimentary uterus and small ovaries; findings were consistent with an endocrine diagnosis of normosmic idiopathic hypogonadotropic hypogonadism (nIHH) ([@MCS005033XUC21]). After clinical evaluation, sex steroid replacement was initiated, and the patient responded with appearance of secondary sexual characteristics, a pubertal growth spurt, and the onset of menses. Her mother had normal menarche at 12 yr of age. Although the patient was referred to our research program at age of 20 yr, this clinical report was initiated upon availability of her exome sequencing (ES) results that were performed more recently. The ES data were available from the index patient and her mother ([Fig. 1](#MCS005033XUF1){ref-type="fig"}). Clinical information and DNA samples from her father and elder sibling were not available.

![Pedigree, multiple species alignments of RAB3GAP2 protein, electropherogram, and *RAB3GAP2* variants identified to date in WARBM/MS. (*A*) Pedigree of index patient and segregation of *RAB3GAP2* variants identified in this report; (*B*) multispecies protein conservation of novel missense variant (p.Arg428Glu) found in index individual showing conservation from humans to zebrafish; (*C*) electropherograms of variants identified in this study; and (*D*) schematic of RAB3GAP2 protein showing MS-associated *RAB3GAP2* variants identified in this report (shown above protein schematic; in green and blue) and *RAB3GAP2* variants reported in the literature (shown below protein schematic). (Red) WARBM-associated variants, (black) MS-associated variants. The RAB3GAP2 protein domains were defined using Interpro ([@MCS005033XUC18]) and Pfam ([@MCS005033XUC5]) resources.](MCS005033Xu_F1){#MCS005033XUF1}

Literature Review of Reproductive Phenotypes in Previously Reported MS Individuals {#s2b}
----------------------------------------------------------------------------------

First, we reviewed genotypes and phenotypes of previously reported individuals with MS with *RAB3GAP2* pathogenic variants ([Table 1](#MCS005033XUTB1){ref-type="table"}). Nine patients (three males, six females; from four families) were identified ([Table 1](#MCS005033XUTB1){ref-type="table"}). Reproductive phenotypes were available in five individuals (three males and two females). Additionally, treatment and olfactory impairment were not reported in the reviewed literature. All three males were prepubertal at the time of report, but each had evidence of neonatal hypogonadism during the neonatal period (i.e., micropenis and/or cryptorchidism). Intriguingly, the reproductive phenotypes noted in the two female patients (ages 17 yr and 14 yr) were reportedly normal. The genotypic spectrum consisted of three homozygous pathogenic missense variants and one homozygous splice-altering variant. In addition to these genetically defined individuals with MS, we also reviewed reproductive phenotypes reported in four patients (three males; one female) without a genetic diagnosis ([Supplemental Table 2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a005033/-/DC1)). Two adult males were reported in the initial report by [@MCS005033XUC17], both of whom had small testes and clinical testing showed elevated gonadotropins but with normal testosterone levels (i.e., compensated hypergonadotropic hypogonadism). [@MCS005033XUC14] reported two patients: a prepubertal boy (age 12 yr) with micropenis and cryptorchidism and a 17-yr-old female with amenorrhea and biochemical evidence of hypogonadotropic hypogonadism.

###### 

Phenotypic and genotypic investigations in individuals with Marsolf syndrome and *RAB3GAP2* variants

                                        [@MCS005033XUC1] (single family)         [@MCS005033XUC12]                        [@MCS005033XUC8] (single family)        Current individual                                                                                                                                                                                      
  ------------------------------------- ---------------------------------------- ---------------------------------------- --------------------------------------- --------------------------------------- --------------------------------------- ----------------------------- ----------------------------- ----------------------------- ----------------------------- --------------------------------------------------------------------------
  Individuals                           IV-1                                     IV-3                                     K43                                     K44.1                                   K44.2 (sibling of K44.1)                P1                            P2                            P3                            P4                            
  Sex                                   Male                                     Female                                   Male                                    Female                                  Female                                  Female                        Female                        Male                          Female                        Female
  Reported age                          11 yr                                    6 yr                                     3.4 yr                                  17 yr                                   14 yr                                   8 yr                          8 yr                          10 yr                         4 yr                          30 yr
  Consanguinity                         \+                                       \+                                       Not reported                            \+                                      \+                                      \+                            \+                            \+                            \+                            No
  *RAB3GAP2* genotype                   c.3154G \> T p.(Gly1052Cys) homozygous   c.3154G \> T p.(Gly1052Cys) homozygous   c.1276C \> T p.(Arg426Cys) homozygous   c.1276C \> T p.(Arg426Cys) homozygous   c.1276C \> T p.(Arg426Cys) homozygous   c.1998 + 1G \> A homozygous   c.1998 + 1G \> A homozygous   c.1998 + 1G \> A homozygous   c.1998 + 1G \> A homozygous   c.1283C \> A p.(Arg428Glu); c.387-2A \> G (likely compound heterozygous)
  Diagnosis                             Martsolf                                 Martsolf                                 Martsolf                                Martsolf                                Martsolf                                ?Martsolf                     ?Martsolf                     ?Martsolf                     ?Martsolf                     Martsolf
  Birth weight                          1870 g                                   3060 g                                   1002 g                                  2470 g                                  2340 g                                  1450 g                        1450 g                        Not reported                  Not reported                  1984 g
  Postnatal growth retardation          \+                                       \+                                       \+                                      \+                                      \+                                      −                             −                             −                             −                             Not recorded
  Postnatal microcephaly                \+                                       \+                                       \+                                      \+                                      \+                                      −                             −                             −                             −                             Not recorded
  Developmental delay                   −                                        −                                        \+                                      \+                                      \+                                      −                             −                             −                             −                             \+
  Intellectual disability               −                                        −                                        Moderate^a^                             Moderate                                Moderate                                −                             −                             −                             −                             Apparent intellectual disability
  Age at walking                        3 yr                                     3 yr                                     3.6 yr                                  −                                       −                                       \+                            \+                            \+                            \+                            2½ yr old
  Speech delayed                        3 yr                                     3 yr                                     \+                                      −                                       −                                       \+                            \+                            \+                            \+                            3 yr old
  Microopthalmia                        \+                                       \+                                       \+                                      \+                                      \+                                      \+                            \+                            −                             −                             −
  Bilateral congenital Cataracts        \+                                       \+                                       \+                                      \+                                      \+                                      \+                            \+                            −                             −                             \+
  Optic nerve atrophy                   −                                        −                                        Pale optic nerves                       \+                                      \+                                      −                             −                             −                             −                             −
  Hypotonia                             \+                                       \+                                       \+                                      \+                                      \+                                      −                             −                             −                             −                             −
  Limb spasticity                       \+                                       \+                                       \+                                      \+                                      \+                                      \+                            \+                            −                             −                             −
  Hypogonadism                          \+                                       Not reported                             \+                                      −                                       −                                       Not reported                  Not reported                  \+                            Not reported                  \+
  Reproductive and genital phenotypes   Micropenis, cryptorchidism               Not reported                             Cryptorchidism and micropenis           Normal                                  Normal                                  Not reported                  Not reported                  micropenis                    Not reported                  Delayed puberty and small ovaries and uterus
  Reproductive endocrine biochemistry   Not reported                             Not reported                             Not reported                            Not reported                            None                                    None                          None                          None                          None                          LH 0.2 IU/L; FSH 0.8 IU/L
  Estradiol: 13.3 pg/mL                                                                                                                                                                                                                                                                                                                                                   

(?Martsolf) Possible Martsolf syndrome, (LH) luteinizing hormone, (FSH) follicle-stimulating hormone, (+) phenotype present, (-) phenotype absent.

^a^"Moderate mental retardation" was claimed by the authors, but no data were provided to support that conclusion.

Exome Sequencing Analysis and Review of the *RAB3GAP2* Allelic Spectrum in WARBM/MS {#s2c}
-----------------------------------------------------------------------------------

The ES data from the index patient were reviewed for known genes reported to cause idiopathic hypogonadotropic hypogonadism including genes reported to cause syndromic forms of IHH ([Supplemental Table 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a005033/-/DC1)). This analysis identified a c.387-2A \> G variant in *RAB3GAP2* (NM_012414.3). This variant had a frequency of 4.1 × 10^−06^ in gnomAD and four independent splice prediction programs (Berkeley Drosophila Genome Project \[BDGP\], Alternative Splice Site Predictor \[ASSP\], Mutation Taster, and Human Splicing Finder) categorized this variant as deleterious secondary to a splicing defect ([Table 2](#MCS005033XUTB2){ref-type="table"}). The proband was also found to harbor a c.1283C \> A variant in *RAB3GAP2*, which predicts p.(Ala428Glu) ([Fig. 1](#MCS005033XUF1){ref-type="fig"}A,B). This variant was novel, disrupted a highly conserved amino acid residue, and predicted as either deleterious/damaging by multiple prediction programs (SIFT, PolyPhen, CADD, and REVEL) ([Table 2](#MCS005033XUTB2){ref-type="table"}). The splice acceptor (c.387-2A \> G) was graded as pathogenic and the missense variant p.(Arg428Glu) was graded as likely pathogenic using American College of Medical Genetics (ACMG) guidlines ([@MCS005033XUC020]). In addition, the proband did not harbor any variants in the coding sequence of other known IHH genes ([Supplemental Table 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a005033/-/DC1)). Although her paternal DNA sample was not available for segregation analysis, her mother shared the c.1283C \> A p.(Arg428Glu) likely pathogenic variant but did not harbor the pathogenic splice variant. The likelihood of the essential splicing variant arising de novo on the maternal haplotype *in cis* with the p.(Arg428Glu) variant was considered. However, we did not perform additional experiments (cell cloning/long-range polymerase chain reaction \[PCR\]) as we deemed that this scenario was unlikely given the previous clear association of biallelic *RAB3GAP2* pathogenic variants with MS. Hence, it was presumed that the variants were most likely to have been inherited in the compound heterozygous state ([Fig. 1](#MCS005033XUF1){ref-type="fig"}C).

###### 

*RAB3GAP2* (NM_012414.3) variants identified in this study and in silico prediction of pathogenicity

  Gene         Chromosome   HGVS DNA          HGVS cDNA        HGVS protein    Variant type   Predicted effect   dbSNP/dbVar ID   Genotype       Exon   Minor allele frequency in gnomAD   In silico prediction^a^                                                                                 Variant classification (ACMG Guidelines)
  ------------ ------------ ----------------- ---------------- --------------- -------------- ------------------ ---------------- -------------- ------ ---------------------------------- ------------------------------------------------------------------------------------------------------- -------------------------------------------
  *RAB3GAP2*   1            220384346T \> C   c.387-2 A \> G   N/A             Substitution   Loss of function   N/A              Heterozygous   5      4.1E-06                            Disease-causing (Mutation tasting; BDGP splice site prediction; ASSP and Human Splicing Finder, CADD)   Pathogenic (PVS1 + PM2 + PP3)
  *RAB3GAP2*   1            220364614G \> T   c.1283 C \> A    p.(Arg428Glu)   Substitution   Missense           N/A              Heterozygous   14     No                                 Deleterious (SIFT, PolyPhen, CADD, and REVEL)                                                           Likely pathogenic (PM2 + PM5 + PP3 + PP4)

^a^In silico prediction programs:

ACMG criteria were based on [@MCS005033XUC020].

Alternative Splice Site Predictor (ASSP) splice site prediction: <http://wangcomputing.com/assp/>.

Berkeley Drosophila Genome Project (BDGP) splice site prediction: <https://www.fruitfly.org/seq_tools/splice.html>.

CADD: <https://cadd.gs.washington.edu/>. (CADD scores = 24.2 in c.387-2A\>G and 28.6 in p.(Arg428Glu).)

gnomAD browser: <http://gnomad.broadinstitute.org/>.

Human Splicing Finder: <http://www.umd.be/HSF/HSF.shtml>.

Mutation Taster: <http://www.mutationtaster.org/ChrPos.html>.

PolyPhen-2: <http://genetics.bwh.harvard.edu/pph2/>.

SIFT: <http://sift.icvi.org/>.

We also cataloged all previously reported *RAB3GAP2* variants in WARBM/MS ([Fig. 1](#MCS005033XUF1){ref-type="fig"}D). Notably, all WARBM-associated *RAB3GAP2* variants were protein-truncating mutations that have been shown to completely abolish RAB3GAP2 function ([@MCS005033XUC12]; [@MCS005033XUC11]). In contrast, including this report, all MS-associated *RAB3GAP2* variants were predominantly missense variants or splicing variants that have been deemed to reduce, but not fully abolish, RAB3GAP2 function.

DISCUSSION {#s3}
==========

This clinical report highlights the index patient\'s clinical odyssey involving multiple diagnostic evaluations without an accurate and timely diagnosis, typifying the clinical challenges posed to both patients and physicians by such rare clinical syndromes. She presented in infancy to ophthalmology with congenital cataracts, to pediatrics in childhood with apparent intellectual disability, and subsequently to endocrinology in adolescence with absent puberty. Eventually, ES identified the two rare variants (pathogenic/likely pathogenic, respectively) in *RAB3GAP*2, a gene previously associated wth the WARBM/MS spectrum ([@MCS005033XUC17]; [@MCS005033XUC24]). The proband had milder phenotypes across the fuller WARBM/MS spectrum, and hence a diagnosis of *RAB3GAP2*-related MS was made several years after her initial clinical presentation, attesting to the utility of genetic testing in providing a unifying clinical diagnosis in individuals with rare syndromic disorders. Furthermore, this study is the first longitudinal description of the reproductive phenotypes (pubertal presentation and biochemical investigations) in an individual with *RAB3GAP2-*associated MS wherein we establish hypogonadotropic hypogonadism as a key pathophysiologic defect in this rare syndrome.

RAB3GAP2 is a GTPase-activating protein, known to form a complex with RAB3GAP1 that together regulates the GTP hydrolysis activity of the Rab protein family of small GTPase(s) with putative exocytotic roles ([@MCS005033XUC10]). Our observations that RAB3GAP2-related MS is associated with hypogonadotropic hypogonadism are consistent with the previously reported interaction of RAB3GAP2 with rabconnectin 3a, a protein expressed in exocytosis vesicles in gonadotropin-releasing hormone (GnRH) axonal terminals in the median eminence of the hypothalamus and in the cells expressing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) within the anterior pituitary gonadotropin-producing cells ([@MCS005033XUC22], [@MCS005033XUC23]). Therefore, we hypothesize that RAB3GAP2-associated hypogonadotropic hypogonadism may also result from defects in hormone release at the hypothalamic and/or pituitary levels. In that regard, it is notable that the first reported individual with MS had hyper- (rather than hypo-) gonadotropic hypogonadism, implicating a primary gonadal defect. To fully establish the precise site of the deficit(s) (hypothalamic vs. pituitary with or without additional gonadal defects) in RAB3GAP2-related WARBM/MS, detailed neuroendocrine studies with GnRH administration will be required, but this was not available for the patient described in this study. In this regard, it is notable that some genetic pathways already implicated as causing reproductive disorders are known to disrupt function at multiple levels across the hypothalamo-pituitary-gonadal axes, resulting in both hyper- and hypogonadotropic phenotypes (e.g., *NROB1/DAX1*, Prader--Willi locus, congenital myotonic dystrophy) ([@MCS005033XUC9]; [@MCS005033XUC6]; [@MCS005033XUC19]; [@MCS005033XUC15]; [@MCS005033XUC2]). Therefore, further longitudinal studies of the reproductive phenotypes along with neuroendocrine studies will be required to fully ascertain the spectrum of reproductive deficits in WARBM/MS.

It has been hypothesized that the severity of the underlying *RAB3GAP2* pathogenic variants ([@MCS005033XUC10]; [@MCS005033XUC12]; [@MCS005033XUC11]) may determine the resultant clinical phenotypes (severe WARBM vs. milder MS). To date, all reported *RAB3GAP2*-related WARBM individuals have harbored homozygous, inactivating variants (frameshifting indels or stop variants). In contrast, the *RAB3GAP2*-related MS genotypic spectrum includes two distinct homozygous missense variants and one homozygous splice-site variant ([Table 1](#MCS005033XUTB1){ref-type="table"}; [Fig. 1](#MCS005033XUF1){ref-type="fig"}D). One of the MS-associated missense mutations (p.Gly1052Cys) was shown to disrupt splicing but produced some preserved full-length protein with likely residual protein function ([@MCS005033XUC1]). Similarly, the second MS-associated *RAB3GAP2* missense variant (p.Arg426Cys) was also deemed not to completely disrupt RAB3GAP2 protein function ([@MCS005033XUC12]). Experimental data on the precise consequence of the MS-associated splice variant have not been reported ([@MCS005033XUC8]). The MS-associated missense mutation identified in this report (p.Ala428Glu) affects a conserved amino acid residue, is predicted to be likely pathogenic by ACMG criteria, occurs close to a previously reported MS-associated variant (p.Arg426Cys), and hence is likely to have reduced functional activity without full abrogation of protein function. The essential splice acceptor variant (c.387-2A \> G) identified in this report is predicted to result in an in-frame deletion (p.Glu130_Arg145del) secondary to skipping of exon 5 of the *RAB3GAP2* gene, with some retained protein function. Thus, in contrast to severe WARBM-associated *RAB3GAP2* variants, almost all of the MS-associated *RAB3GAP2* variants (including this report) retain some residual protein function, and these findings lend further support to prior observations that the severity of the variants underlie genotype--phenotype correlations ([@MCS005033XUC10]; [@MCS005033XUC12]; [@MCS005033XUC11]). However, as shown in [Table 1](#MCS005033XUTB1){ref-type="table"}, expressivity is still variable across families harboring the less severe *RAB3GAP2* variants, which suggests that there may be other genetic/nongenetic modifiers that determine the clinical phenotype. In this regard, because our ES analysis was restricted to genes linked primarily to idiopathic hypogonadotropic hypogonadism, the potential contribution of other genes to the variable phenotypic expressivity could not be examined, and this represents a limitation of this current study.

A key challenge in accurate and timely diagnosis of complex syndromes relates to "temporal gaps" in the recognition of constituent phenotypes that become evident across the life span at various developmental stages. For example, in WARBM/MS, congenital cataracts and neurological features (developmental delay, intellectual disability, and spasticity) are recognized in early in childhood, whereas reproductive phenotypes are typically not readily evident in childhood. In this regard, our clinical observation that WARBM/MS is characterized by hypogonadotropic hypogonadism is particularly important. It is now established that the reproductive cascade is paradoxically active in the first few months of life in both sexes ([@MCS005033XUC7]). During the first 6 mo in boys and ∼12 mo in girls, sex-steroid and gonadotropin levels are equivalent to those observed in adulthood, and this developmental window is referred to as the minipuberty of infancy ([@MCS005033XUC4]). Micropenis and/or cryptorchidism (undescended testes) in boys may be signs of absent minipuberty in boys and laboratory assessment of gonadotropin levels at this developmental window may indicate hypogonadotropic hypogonadism. Indeed, in all of the males with RAB3GAP2-related MS, evidence of a defective minipuberty was readily evident (micropenis/cryptorchidism) and, thus, in conjunction with other clinical signs, a diagnosis of MS was feasible ([Table 1](#MCS005033XUTB1){ref-type="table"}). Furthermore, recognition of hypogonadotropic hypogonadism in boys also allows the administration of neonatal testosterone/hCG therapy to help promote penile growth and alert the observant physician about the need for diligent prospective endocrine evaluation during adolescence. This recognition helps timely initiation of secondary sexual characteristics, optimizes adult height/bone health, and avoids much of the psychological sequalae of delayed puberty. In sharp contrast to boys, disruption of minipuberty in girls is typically not recognizable as there are no physical signs that are readily evident in infant girls. Indeed, in the patient described in this report, although ocular/neurological phenotypes were recognized early, a diagnosis of WARBM/MS was not feasible because hypogonadism, a key defining feature of WARBM/MS, could only be demonstrable at adolescence when pubertal failure became evident. Hence, in girls presenting with ocular and neurological signs of WARBM/MS (and in boys without discernible micropenis/cryptorchidism), genetic testing must be considered to allow an earlier molecular diagnosis of the WARBM/MS spectrum that will facilitate prospective endocrine evaluations and multidisciplinary involvement including optimal endocrine care and timely initiation of sex-steroid therapy.

In summary, this report illustrates the emerging importance of human genetics and next-generation sequencing in providing a unifying clinical and molecular diagnosis in rare syndromic presentations of IHH. These combined approaches additionally provide a unique opportunity to catalog the mutational and phenotypic spectrum of these syndromes and inform the pathophysiology, clinical care, and recurrence risk assessments.

METHODS {#s4}
=======

This research was approved by the Partners Institutional Review Board at the Massachusetts General Hospital. The family participated in this study after their informed consent was obtained.

Genetic Analysis {#s4a}
----------------

ES was performed at The Broad Institute Genomics Platform. Variant calling was performed with GATK creating gVCF files for each sample that were then jointly called using the GATK Genotype gVCF module. Variant quality scores were derived using GATK best practices for indels and single-nucleotide variants. The jointly called VCF files were then analyzed using the integrative database framework, GEMINI v.0.19.1. Variant annotation was performed with the Ensembl Variant Effect Predictor (VEP) against the GRC37/hg19 reference Human Genome. Rare sequence variants (RSVs) for both homozygous and heterozygous RSVs were based on a minor allele frequency (MAF) of \<0.1% as determined by the genome Aggregation Database (gnomAD) browser ([@MCS005033XUC16]). All RSVs were confirmed in bidirectional Sanger sequencing in all probands and their pattern of segregation established in all available family members. ES coverage for the *RAB3GAP2* is shown in [Table 3](#MCS005033XUTB3){ref-type="table"}. Sanger sequencing was performed by the Center for Computational and Integrative Biology (CCIB) DNA Core Facility at Massachusetts General Hospital (Cambridge, MA). The ES data from the index patient were reviewed for known genes associated with syndromic and nonsyndromic IHH ([Supplemental Table 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a005033/-/DC1)). The protein domains were defined using InterPro ([@MCS005033XUC18]) and Pfam ([@MCS005033XUC5]) resources.

###### 

Exome sequencing coverage table for the *RAB3GAP2*

  Sample    Percentage of reads aligned   Average read coverage   Percentage of *RAB3GAP2* sites with 10× coverage
  --------- ----------------------------- ----------------------- --------------------------------------------------
  Proband   94%                           136.5                   99%

Literature Review {#s4b}
-----------------

PubMed was searched for original full-text articles (English language) published up to November 2019 discussing Martsolf syndrome and *RAB3GAP2*-associated WARBM/MS. The search keywords included "Martsolf syndrome," "Warburg-Micro syndrome," "phenotype," "genotype," "RAB3GAP2," "genetics," "gene mutation," and "variant." Relevant articles of individuals with MS, genotypes, and endocrine phenotypes were collated.

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
--------------------------

All sequence data and interpreted variants have been deposited in ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>) under accession numbers SCV001245468 and SCV001245469.
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